Wells Fargo Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $25
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Larry Biegelsen maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight and lowers the price target from $27 to $25.
Wells Fargo analyst Larry Biegelsen maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight and lowers the price target from $27 to $25.